Clinical need and product fit
Is the unmet need specific, material and linked to a product that can fit the intended users, workflow and market?
Medtech due diligence
See the operating risk behind the narrative.
Genvissa gives investors, acquirers, licensors and boards an independent view of whether a medtech proposition is technically credible, evidence-ready and realistically executable.
Independent challenge
A compelling story can still conceal a fragile critical path.
The key question is whether the technology, product plan, evidence and company can support the value being claimed.
Medtech risk is rarely confined to one function. A regulatory route can depend on the intended use, a clinical claim can depend on product performance, and a manufacturing plan can undermine both cost and scale.
Genvissa assesses those dependencies as one system, distinguishes material risk from ordinary development work and translates findings into decision consequences.
Scope of review
The questions that can change the investment case.
Technical credibility
What has actually been demonstrated, under what conditions, and what remains uncertain about performance, integration and scale?
Claims and evidence
Are the intended claims clear, and is the analytical, technical, clinical and usability evidence sufficient and appropriately sequenced?
Quality and regulatory route
Is the classification and route credible, are standards and QMS needs understood, and is the plan proportionate to the product and markets?
Manufacturing and execution
Can the company develop, transfer, manufacture and control the product within the stated budget, team, partnerships and timeline?
Commercial and adoption logic
Does the proposition connect to a buyer, evidence requirement, payment route, pathway need and realistic route to adoption?
Risk-focused review
Structured assessment of the data room, management narrative, product plan, evidence, regulatory route, supply chain and commercial assumptions.
Management questions
Prioritised questions that expose the assumptions, evidence gaps and operating dependencies most likely to affect value or timing.
Material findings
A concise view of strengths, red flags, uncertainties, mitigations and the implications for the investment, acquisition or licence.
Value-creation plan
A practical 90-day or milestone-based plan for controlling risk, strengthening evidence and building the next credible value inflection.
Engagement design
Proportionate to the decision and available evidence.
Scope can range from a focused technical review to an integrated company and product assessment. Limitations, unresolved questions and reliance on specialist opinion are made explicit.
Can you work directly for an investor or acquirer?
Yes. The review is framed around the client's decision, confidentiality requirements and the evidence that can reasonably be assessed within the transaction timeline.
Do you provide formal legal or regulatory opinions?
Formal specialist opinions are identified and brought in where required. Genvissa integrates those inputs into the wider technical, operating and commercial decision.
Can you support the company after investment?
Yes. Findings can be translated into a controlled value-creation programme or fractional leadership remit with clear owners, evidence and decision gates.
Before capital is committed
Test what must be true for the investment case to hold.
Share the decision, stage and diligence window, and we will quickly establish the right scope.